Buoyed by the fast paced growth clocked by its biosimilars business, Hyderabad-based pharma giant Dr Reddy’s Laboratories, which just last month inked a pact with German pharma biggie Merck Seroni for biosimilar co-development, is trying to replicate its success with generic drugs in regulated markets with biosimilars as well. The company, which clocked USD 26 million sales of biosimilars during fiscal 2011-12, is now planning to introduce its biosimilars in developed markets, DRL chairman K Anji Reddy said in the company’s annual report for 2011-12. The company’s revenues from biosimilar have shown a CAGR of 39% from fiscal 2007-08.
